Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | CD69 | Q07108 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165691 | 1.00 | BTK (0.70) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL20480850 | 1.00 | BTK (0.70) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL24363230 | 0.91 | BTK (0.69) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL24363496 | 0.89 | BTK (0.68) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14165430 | 0.87 | BTK (0.66) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14165264 | 0.83 | BTK (0.61) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14165263 | 0.83 | BTK (0.61) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14165578 | 0.82 | BTK (1.00) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14241806 | 0.82 | BTK (1.00) | BTKKCNH2EGFRTECBMX | |
| SCHEMBL14165837 | 0.82 | BTK (1.00) | BTKKCNH2EGFRTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4056562-A1 | HETEROCYCLIC INHIBITORS OF BRUTON'S TYROSINE KINASE | Merck Patent GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| EP-2718270-B1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-9580449-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9073947-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| EP-2718270-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | Merck Patent GmbH (DE) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170976-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | BTK 1/4885KCNH2 2447/4885EGFR 219/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | BTK 1/4885KCNH2 2447/4885EGFR 219/4885 |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | BTK 1/4885KCNH2 2447/4885EGFR 219/4885 |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | BTK 1/4885KCNH2 2447/4885EGFR 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.